RDHL-
Select 2016 milestones include:*


Successful final results from the first Phase III study with RHB-105 for

the treatment of _H. pylori_ infection

Positive and unanimous independent DSMB recommendation for the

continuation of the Phase III study with RHB-104 for Crohn's disease (the

MAP US study)

Encouraging top-line final results from the Phase IIa proof-of-concept

study with RHB-104 for relapsing-remitting multiple sclerosis

Exclusive U.S. co-promotion agreement with Concordia for

gastrointestinal drug Donnatal(R)

*Select potential milestones expected in 2017:*

Initiation of a confirmatory Phase III study with RHB-105 for the

treatment of _H. pylori_ infection, expected in Q2/2017

Second independent DSMB meeting for the MAP US Phase III study with

RHB-104 for Crohn's disease, including an interim efficacy analysis and an

evaluation of an option for early stop for success for overwhelming

efficacy, expected in Q2/2017

Top-line results from the BEKINDA(R) Phase III study for gastroenteritis

(the GUARD study), expected in Q2/2017

Top-line results from the BEKINDA(R) Phase II study for IBS-D, expected

mid-2017

Initiation of promotional activities for Donnatal(R) in selected U.S.

territories